PBHPrestige Consumer Healthcare Inc.

Healthcare

$47.84-23% 1Y

$47.84

$44.7652 weeks$70.21

Is the price fair?

Good

Undemanding: modest expectations priced in and cheap vs its sector.

2 good, 1 neutral

What the price assumes~−4% a year

Priced for a decline (~−4% a year). Little growth is priced in even as revenue fell 1% a year over three years, potential value, or a value trap.

Vs its own P/E rangemid-range for this companyderived

In its normal range: P/E 13.4 vs a 15.4 median over 33 quarters (−13% vs median).

Vs sector (EV/EBIT)14.5×

Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)better than 78% of the market

FCF yieldbetter than 87% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What PBH's price assumes

Prestige Consumer Healthcare Inc. trades at 13.4× earnings against 21.0× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.

13.4

Trailing P/E · Drug Manufacturers - Specialty & Generic median 21.0 · cheaper than the typical name in its group

Price / sales: 2.05
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 10%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
Growth the price implies: −4.2%
Growth the price implies · The price pays for −4.2% free cash flow growth a year for a decade; the business has delivered +3.6% a year over the last three.

Details›

Price / booktoday's price, trailing year to Jun 30, 2026: 1.18
EV / EBITtoday's price, trailing year to Jun 30, 2026: 14.5
EV / salestoday's price, trailing year to Jun 30, 2026: 3.80
Healthcare median P/E503 names: 27.9
Drug Manufacturers - Specialty & Generic median P/E44 names: 21.0
Free cash flow, trailing twelve months: $235M
Market capitalisation47.4 million shares, counted Jul 31, 2026: $2.27B
3-year revenue growth: −0.75%
3-year free cash flow growth: +3.6%

What the market has paid for these earnings: 33 quarters of its own multiple × $3.57 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$46.78
Its own P/E history, median	$55.14
Its own P/E history, upper quartile	$66.76
52-week range	$44.76 – $70.21
Today	$47.84

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.